Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of suvratoxumab to prevent nosocomial pneumonia in mechanically ventilated ICU patients with lower respiratory tract S. aureus colonization
MOH_2022-06-13_010819Phase 3Not yet recruiting
- Sponsor
- Aridis Pharmaceuticals, Inc.
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hospital-acquired pneumonia (HAP) comparing Suvratoxumab with Placebo (2 arms). Primary endpoint: Incidence of all-cause nosocomial pneumonia. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
Suvratoxumab
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on MOH_2022-06-13_010819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-06-13_010819.